A senior executive at a pharmaceutical company focused on women’s health said the sector was chronically undervalued because the investment world is dominated by men.
Susanne Fiedler, chief commercial officer of Merck spin-off Organon, said investors often assumed that women’s specific health needs were limited to reproductive health, whereas common autoimmune and cardiac conditions could hit women much harder, or in different ways.
Investing was still “a bit of a men’s world”, she told the Financial Times. “I think the fact that most of them are men is not always helpful . . . We cannot assume that people understand